Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 28, 2024; 30(24): 3120-3122
Published online Jun 28, 2024. doi: 10.3748/wjg.v30.i24.3120
Managing immune checkpoint inhibitor-associated gastritis: Insights and strategies
Li-Li Yu, Zhi-Lin He, Xin-Lai Qian
Li-Li Yu, Zhi-Lin He, Xin-Lai Qian, Department of Pathology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang 453003, Henan Province, China
Li-Li Yu, Zhi-Lin He, Xin-Lai Qian, Department of Basic Medical Sciences, Xinxiang Medical University, Xinxiang 453003, Henan Province, China
Author contributions: He ZL drafted the manuscript; Yu LL edited and revised the manuscript; Qian XL revised the letter and approved the final version of the manuscript.
Supported by the National Natural Science Foundation of China, No. 81671226; Natural Science Foundation of Henan Province, No. 232300421047; Science and Technology Innovation Talents in Universities of Henan Province, No. 24HASTIT067; and Henan Province Young and Middle-aged Health Science and Technology Innovation Talent Project, No. JQRC2023001.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Li Yu, PhD, Associate Professor, Department of Basic Medical Sciences, Xinxiang Medical University, No. 601 Jinsui Road, Xinxiang 453003, Henan Province, China. merrys222@126.com
Received: April 21, 2024
Revised: June 5, 2024
Accepted: June 13, 2024
Published online: June 28, 2024
Processing time: 65 Days and 0.1 Hours
Abstract

Immune checkpoint inhibitors (ICIs) are widely used due to their effectiveness in treating various tumors. Immune-related adverse events (irAEs) are defined as adverse effects resulting from ICI treatment. Gastrointestinal irAEs are a common type of irAEs characterized by intestinal side effects, such as diarrhea and colitis, which may lead to the discontinuation of ICIs.

Keywords: Immunotherapy; Immune checkpoint inhibitor; Immune checkpoint inhibitor-related gastritis; Immune-related adverse events; Autoimmune responses

Core Tip: Immune checkpoint inhibitor (ICI)-related gastritis is rare but may lead to serious complications such as gastrorrhagia. The strategies such as early identification, pathological diagnosis, management interventions, and immunotherapy reactivation are discussed to enable clinicians to better manage ICI-related gastritis and improve the prognosis of these patients.